announcement, page-22

The news received yesterday was another clear signal not only to the investment community but also to the scientific community that Neuren are ready about executing on their development and commercialisation strategy.

Do I think Neuren will take their Rett Syndrome program all the way to completion themselves? Yes, more than ever. I do for reasons highlighted in many of my previous posts. I thought they would have even before this news was announced.

Does the funding now in place open up many other possibilities for the rare/orphan disease targets that Neuren have hinted on in previous presentations and announcements? Yes it does. Idiopathic Austism is the next I would look out for.

Do I think a partnering deal will be struck for the company's lead molecule NNZ-2566 prior to or after Rett Syndrome results are known? No I don't. Think about why they've gone down the route of cashing up now.

As I have hinted at in previous posts, (and it's just my thoughts) I don't think this company will sell themselves short with a partnering deal on their lead molecule. Neuren are 100% focused on a positive signal from their Rett Syndrome program. Once that is known, I believe this company has the potential to be sold for multi multi billions of dollars.

Do I think the multiple share price rise from 1.3c to 12c (9 times previous cap raise) will once again be repeated leading up to results? Yes I do. That would be a share price of over $1 pre-results. Have a look at the unique biology of NNZ-2566, the strong financial position the company is now in and the possibilities that are about to open up from here. The opportunity to buy at these levels will not last very long. The gates are about to be open once again. I hope the market is prepared.

Regards,
Tony